Delta-2 tubulin for detection and treatment of peripheral neuropathy
This technology identifies delta-2 tubulin as a biomarker and potential therapeutic target for chemotherapy-induced peripheral neuropathy.
Unmet Need: Effective methods for prevention and treatment of chemotherapy-induced peripheral neuropathy
Current methods to treat chemotherapy-induced peripheral neuropathy (CIPN) involve modification of chemotherapeutic agents and administration of opioids or antiepileptic drugs. However, modifying chemotherapy regimens can prevent patients from receiving effective cancer treatment, and CIPN can persist even after termination of chemotherapy. Additionally, current pharmacological interventions for management of CIPN are either ineffective or unsuitable for most patients. Therefore, there is a need for effective methods to prevent and treat CIPN.
The Technology: Delta-2 tubulin for diagnosis and treatment of chemotherapy-induced peripheral neuropathy
This technology identifies delta-2 tubulin as a biomarker of peripheral neuropathy and provides methods for identifying compounds with therapeutic and/or preventative potential. While current methods focus on managing CIPN symptoms, this technology utilizes delta-2 tubulin expression in patient samples to determine the likelihood of developing CIPN following chemotherapy. Additionally, various potential therapeutics and associated screening assays are provided. The methodology described allows for a more individualized and aggressive chemotherapeutic approach for cancer patients, while offering treatment and preventative strategies for CIPN.
This technology has been validated with primary cultured peripheral neurons from patients, as well as with rat and human neuronal tissue.
Applications:
- Diagnostic method for CIPN
- Treatment strategies for CIPN
- Drug screening for therapeutic and/or preventative agents against CIPN
- Chemotherapeutic agent screening
Advantages:
- Provides individualized screening and diagnostic method for CIPN
- Provides a preventative strategy for minimizing effects of CIPN
- Allows for monitoring of CIPN probability over the course of chemotherapy
Lead Inventor:
Patent Information:
Tech Ventures Reference:
IR CU18162, CU18161
Licensing Contact: Ron Katz